The use of NOACs demonstrated an increasing trend over the study period, with a higher proportion of patients being prescribed these medications in recent years (4% in 2019 to 30% in 2023–2024). 4.3.
← all excerpts
Novel Oral Anticoagulants Versus Antiplatelet Therapy in Post-TAVR Patients: A Single-Center Retrospective Study.
1
—
—